FDA approves CYRAMZA (ramucirumab) first-line treatment of metastatic EGFR mutation non-small cell lung cancer
-
Last Update: 2020-06-05
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
About 50% of non-small cell lung cancer (NSCLC) patients had advanced or metastatic diseases at the time of first diagnosis, and the five-year survival rate in patients with metastatic NSCLC was 6%In the United States, about 15% of NSCLC patients have EGFR mutationsLilly announced today that the U.SFDA has approved cyRAMZA ® (ramucirumab, 10 mg/mL solution) in combination with the first-line treatment of epidermal growth factor receptor (EGFR) epidermis 19 missing or exogenous 21 mutation (L858R) of the metastatic NSCLCCYRAMZA HAS NOW RECEIVED SIX FDA APPROVALS TO TREAT LUNG, LIVER, STOMACH AND COLORECTAL CANCERSCYRAMZA combined with erlotinib is the first FDA-approved anti-VEGFR/EGFR TKI combination therapy for the treatment of metastatic EGFR mutation NSCLCThis approval is based on the validity and safety results of the Phase III RELAY studyIn the RELAY study, CYRAMZA was combined with the target EGFR tyrosine kinase inhibitor (TKI) erlotinib, with no progression in the combined treatment group (PFS) at 19.4 months, compared with 12.4 months (p 0.0001) in the placebo groupThe effect of PFS was the same in the subgroup of the exon 19 missing and the exon 21 mutationMore importantly, the CYRAMZA combination treatment reduced the risk of progression or death by 41%
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
